Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
October 1, 2024
Earnings Call Speaker Segments
Operator
operatorJust to remind everyone, this conference call is being recorded. Before we get into our remarks, I'd like to remind you that statements made by Palatin are not historical facts and may be forward-looking statements. Such statements rest on assumptions that may or may not prove accurate, and actual results could differ materially from those anticipated because of the variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission. Please weigh those risks and uncertainties carefully as you evaluate these forward-looking statements by Palatin's prospects. Now I'd like to turn the call over to our host, Dr. Carl Spana, President and Chief Executive Officer of Palatin. Please go ahead.
Carl Spana
executiveThanks. Morning, everyone, and thanks for joining Palatin's year-end fiscal 2024 call. I'm Dr. Carl Spana, CEO and President of Palatin. Joining me today is Steve Wills, Palatin's Chief Financial Officer and Chief Operating Officer. At this point I'll hand things over to Steve, who will provide the financial update.
Stephen Wills
executiveThank you, Carl. Good morning, and good afternoon to all of you. Ahead of walking through the financial results, there are a few additional corporate matters I want to point out. On Vyleesi, bremelanotide injection — a commercial product that Palatin developed for hypoactive sexual desire disorder, or HSDD — Palatin completed an asset sale to Cosette Pharmaceuticals worth as much as $171 million in December 2023. The terms comprised $12 million upfront, along with potential milestones totaling as much as $159 million tied to annual net sales, spanning from $15 million to $200 million. Importantly, Palatin keeps the rights to bremelanotide, and its use, for obesity and male treatment indications. Turning to financings, in the fiscal year that ended June 30th, 2024, Palatin brought in total gross proceeds of $21 million through registered direct and warrant inducement offerings. Now, on Palatin's financial results for the fourth quarter and fiscal year ended June 30th, 2024: total revenue is made up of gross product sales of Vyleesi, net of expenses, allowances, and accruals, plus license and contract revenue. Following the closing of the sale of the Vyleesi rights for female sexual dysfunction to Cosette Pharmaceuticals in December of 2023 — again, for up to $171 million — Palatin recorded no product sales for the fourth quarter ended June 30th, 2024. In the fourth quarter ended June 30th, 2023, gross product sales came to $4.1 million, and net product revenue was $1.8 million.
Stephen Wills
executiveFor the fiscal year that closed June 30, 2024, Vyleesi gross product sales to pharmacy distributors came in at $8.9 million, with net product revenue of $4.5 million. That compares with gross product sales of $12.5 million and net product revenue of $4.9 million in the prior fiscal year. Total operating expenses for the fourth quarter ended June 30, 2024, were $8.7 million, versus $12.6 million in the comparable quarter last year. That decline came mainly from lower spending on our MCR, melanocortin receptor programs, and secondarily from the elimination of selling expenses related to Vyleesi. For the fiscal year ended June 30, 2024, total operating expenses were $27 million, compared to $37.3 million in the prior fiscal year. This decrease was mainly due to the $7.8 million gain recognized on the sale of Vyleesi and secondarily to the elimination of related selling expenses. Turning to cash flows, Palatin's net cash used in operations for the quarter ended June 30th, 2024, was $6.5 million, compared to net cash used in operations of $9.6 million for the same period in 2023. This decrease in net cash used in operations is mainly due to the decrease in operating expenses and secondarily to working capital changes. Palatin's net cash used in operations for the fiscal year ended June thirtieth, 2024, was $31.5 million, compared to net cash used in operations of $29.3 million for the same period in 2023.
Stephen Wills
executiveThat rise in net cash used in operations came about because of working capital changes and higher payments tied to inventory purchase commitments. For the quarter and fiscal year ended June 30, 2024, Palatin's net loss was $8.6 million and $29.7 million, respectively, versus a net loss of $9.8 million and $24 million, respectively, for the same period in 2023. Those variances were covered above under the revenue and operating expenses. Turning to our cash position, as of June 30, 2024, Palatin's cash and cash equivalents stood at $9.5 million, compared to cash and cash equivalents of $10 million as of March 31, 2024, and $8 million, along with $3 million in marketable securities, as of June 30, 2023. We at Palatin are actively engaged with multiple parties regarding potential funding sources for future operating cash needs, consisting of both business development efforts and other potential collaborators, including entities involved with the same programs that Palatin is advancing. Thank you, and I'll now turn the call back over to Carl.
Carl Spana
executiveThanks, Steve. Fiscal 2024 proved to be an exciting year for Palatin, with substantial growth across every one of our pipeline programs. The results confirm that targeting the melanocortin system can yield therapeutics that are safe, effective, and differentiated — ones capable of improving patients' lives and meeting unmet market needs. Today I'll walk through some of the significant achievements in each of our therapeutic areas. Because Steve has already covered the Vyleesi sale to Cosette, I'll move on and begin with some of our ocular programs. We have multiple ocular programs that made significant progress over the past year. PL-9643 is Palatin's topically administered product for treating the signs and symptoms of dry eye disease. We successfully completed the first phase 3 trial, MELODY-1, and announced the positive results earlier in the year. Current FDA-approved treatments for dry eye disease have three significant problems that limit their utility. They have poor ocular tolerability, lack broad efficacy, and they take a long time to have symptom relief. The results of MELODY-1 clearly demonstrated that PL-9643 is a truly differentiated treatment for dry eye disease that solves the three main problems of current treatments. The PL-9643 MELODY-1 trial showed that PL-9643 had excellent ocular tolerability, broad efficacy in multiple signs and symptoms, and demonstrated efficacy as early as two weeks.
Carl Spana
executiveGiven this emerging product profile, PL-9643 could become the leading treatment for dry eye disease. To summarize, in the MELODY-1 phase 3 trial, results versus vehicle control included the following. PL-9643 reached statistical significance for the co-primary endpoint of ocular pain across seven of the secondary symptom endpoints, including eye dryness and ocular discomfort. As far as we know, no FDA-approved treatment for dry eye disease has demonstrated such a broad effect on the symptoms of dry eye disease. For inferior corneal fluorescein staining, which is a sign, and we have agreement with the FDA that this will be the primary sign endpoint for the next phase 3 trial, and PL-9643 also achieved statistical significance at the two-week time point in MELODY-1. PL-9643's positive effects on the signs and symptoms of dry eye disease were rapid, with efficacy at two weeks after starting treatment, and they continued to improve over the twelve weeks of the treatment. PL-9643 has excellent ocular tolerability, with no subjects discontinuing the study due to an ocular adverse event. Data for approved dry eye disease treatments shows that a lack of efficacy and poor tolerability, such as burning, blurry vision, bad taste, stinging, has led to a significant amount of patient dissatisfaction and high discontinuation rates.
Carl Spana
executiveDuring a recent Type C meeting, the FDA came to an agreement with us regarding our strategy for the remaining work needed to submit a new drug application to the FDA seeking approval of PL-9643 for treating the signs and symptoms of dry eye disease. To be specific, we have FDA concurrence on our protocols, the subject count, the primary sign and symptom endpoint, and our statistical analysis plan. We are prepared to finish the PL-9643 phase 3 program, with every remaining clinical study carried out and wrapped up during calendar year 2025, and we expect to file the NDA in the first half of calendar year 2026. Our two other ocular programs likewise achieved meaningful progress in fiscal 2024. PL-9588 is our topically administered candidate being developed for glaucoma treatment. Over the last year, we finished a comprehensive assessment of PL-9588 across multiple preclinical glaucoma models. Findings show that PL-9588 both reduces intraocular pressure and delivers direct neuroprotection. Direct neuroprotection of the optic nerve represents a significantly differentiating factor compared with current glaucoma treatments, and PL-9588 is now prepared to start the IND-enabling studies, with clinical trials commencing in calendar year 2025. Retinopathies constitute a broad category of ocular diseases that damage the retina and can result in vision loss.
Carl Spana
executiveBy 2030, the worldwide market for treatments is projected at roughly $30 billion. Our differentiated novel therapy for various retinopathies is PL-9654. During fiscal 2024, we finished a thorough assessment of PL-9654 across several retinal disease models. PL-9654 showed it can preserve vision, shield the retina from damage, and in genomic analysis it favorably influenced multiple pathways recognized as involved in retinal disease progression. We additionally achieved considerable headway on an intravitreal injectable formulation, and PL-9654 is now prepared to begin IND-enabling studies in calendar 2025. I'll now turn to our MC4R, meaning melanocortin-4 receptor, obesity program. Medication for obesity is by now well established and expanding quickly. We need multiple drugs with differing mechanisms of action that affect weight loss and, importantly, weight loss maintenance. Given the key role the MC4R receptor has in regulating stored energy and food intake, we firmly believe MC4R agonists will form an important part of the future of obesity treatment and weight loss management. Palatin has a long-running research effort aimed at developing melanocortin therapeutics that selectively activate the MC4R receptor as treatments for obesity and weight loss maintenance.
Carl Spana
executiveGiven how much work we've done on melanocortin agonists for obesity treatment—designing and developing them, with 2 clinical studies already finished and published—we're in a strong position to lead in creating melanocortin-based therapeutics for losing weight and keeping it off. As you're all surely aware, incretin-based treatments like Zepbound and Wegovy are the mainstay for obesity, and their growth has been impressive. That said, as many as 67% of patients who start treatment stop within the first year, largely because of side effects and a plateau effect, and they frequently put back the weight they lost quite quickly. We need additional approaches so patients have a chance to reach their weight loss goals safely and tolerably. Research from Palatin and academic groups suggests that pairing MC4R receptor agonists with GLP-1 receptor agonists such as tirzepatide could produce synergistic effects on weight loss, enabling greater or maintained weight loss at lower, better-tolerated doses. To explore whether an MC4R receptor agonist adds benefit when combined with a GLP-1 receptor agonist, we began a phase 2 clinical study in August. In this study, obese subjects will receive the MC4R receptor agonist bremelanotide together with tirzepatide. The trial is designed to enroll approximately 60 obese subjects across four sites in the US.
Carl Spana
executiveThe main goal is to show that giving bremelanotide together with tirzepatide is safe and works better than tirzepatide by itself at bringing body weight down. For four weeks, patients will get tirzepatide once a week; after their eligibility is confirmed, they'll be randomized into one to four arms, which involve weekly and daily study drugs — weekly tirzepatide plus daily bremelanotide. A range of safety and efficacy assessments will be run so we can better characterize how well bremelanotide performs both as a standalone obesity treatment and when combined with GLP-1 therapy. Enrollment for this study should be finished this quarter, with data arriving in the first quarter of calendar 2025. We have also created next-generation melanocortin-four receptor peptide agonists that are highly selective, along with small molecules, for obesity treatment and weight loss maintenance. Our new MC4R peptide agonists are extremely selective for the MC4R receptor over the MC1R receptor, and we don't expect skin darkening to occur as a side effect. A proprietary technology underpins their design so that dosing happens once a week. Final lead selection is expected in the first quarter of calendar 2025, followed by an IND and first-in-human clinical studies in the second half of calendar 2025. Let's now turn to what we're doing in sexual dysfunction.
Carl Spana
executiveOur work looking at melanocortin agonists for treating a range of male-to-female sexual dysfunctions has produced a novel product, a co-formulation combining bremelanotide with a phosphodiesterase five inhibitor. Such compounds include Viagra and Cialis. In our view, this product may be an ideal treatment for the 35% of men suffering from erectile dysfunction who respond inadequately to PDE5 inhibitor therapy. These patients have few options available and make up a large underserved market. We have launched a development and clinical program to evaluate bremelanotide co-formulated with a PDE5 inhibitor for treating erectile dysfunction in patients who are non-responsive to PDE5 inhibitor monotherapy. A pharmacokinetic study should begin in the first half of calendar 2025, and enrollment of patients in a phase 2 clinical study is anticipated during the second half of calendar 2025, with top-line results in 2026. The last program I want to discuss is PL-8177 for ulcerative colitis, which is in a phase 2 study evaluating oral PL-8177, a selective melanocortin-1 receptor agonist, in patients with ulcerative colitis. Enrollment in the study is nearly complete, and we expect data from the interim analysis later this quarter. Supporting the oral PL-8177 program, our clinical and preclinical studies show that treatment with oral PL-8177 causes diseased colons to improve toward a healthy state and to resolve inflammation.
Carl Spana
executiveWhen we resolve inflammation instead of blocking it, that opens up the possibility of efficacy along with safety that is significantly differentiated in the treatment of colitis and inflammatory bowel diseases. Looking ahead, we want to keep building on what we achieved over the past year by concentrating on continued development of our key programs in obesity and dry eye disease. Importantly, collaborations and partnerships for our dry eye disease program, our other ocular programs in glaucoma and retinopathies, and our ulcerative colitis program. Upcoming milestones and activities for our novel and differentiated programs include the following: For the MC4R obesity program, we want to complete the phase 2 study evaluating co-administration of bremelanotide and tirzepatide, and we expect that data to be reported out in the first quarter of calendar 2025. We also are on track to move our selective MC4R long-acting peptide agonist through first-in-human studies and to advance the program toward a phase 2 dose-ranging efficacy during calendar year 2025. For our dry eye disease program, we want to start and complete the phase 3 trials, MELODY-2 and MELODY-3, with data expected by calendar year-end 2025. And also, we want to complete all manufacturing activities needed to file a new drug application with the FDA in the first half of calendar 2026.
Carl Spana
executiveSo to help push this program ahead, we’re actively talking with possible corporate collaborators and funding partners. For the male sexual dysfunction program, we want to get the pharmacokinetic study underway and finished during the first half of calendar year 2025, and to start recruiting patients for a phase two/three study, which is expected to begin in the second half of calendar 2025. Also important, we’ve stepped up our business development efforts to support licensing of our major programs as well as our earlier pipeline programs. Steve, myself, and the entire Palatin team feel extremely excited and enthusiastic about what these programs could do by bringing novel, innovative treatments that improve patients’ lives and address significant unmet medical needs. At this point we’ll open the call for questions.
Operator
operatorAbsolutely. We're opening the floor to questions now. Should you have a question or comment, please press star one on your phone at this time. When asking your question, we ask that you pick up your handset if you're listening on a speakerphone, so sound quality is optimal. Please hold for just a moment while we poll for questions. Our first question comes from Joe Pantginis with H.C. Wainwright. Please ask your question. Your line is live.
Joe Pantginis
analystHi everyone, appreciate the information and thanks for taking my question. So I have two groups of questions. First, regarding your weight loss program with GLP-1, I wanted to discuss what the study's benchmarks for success are. Are you seeking a minimum or a threshold for weight loss in order to proceed to the next stage? What effects are there on lean muscle mass? I hope you can share that with us, and also what you plan to do to eliminate, alleviate, or mitigate some of the pigmentation issues?
Carl Spana
executiveSure. All right, Joe, there are several things to cover there. So let me address what we expect from the ongoing phase II trial, in which bremelanotide is being given together with tirzepatide. The key primary question is whether an additive effect exists. That could mean one plus one equals two, one plus one equals three, and so forth. So the primary analysis will compare the co-administered combination against tirzepatide alone. And nothing is fixed. What we're essentially seeking is a measurable or significant separation. Now, these patients aren't on long-term treatment, so their weight losses won't be, you know, 10, 15% over four weeks. You're going to be in that 2%-3% range, 2%-5% range. We want to see an additive effect, which we believe, given the design and given what we expect to observe, we should be able to achieve. So again, it's not — you know, we're not using — again, this isn't a long-term study where you'd expect, you know, explosive numbers, but we really should see a very clear signal from the study that these two are additive or synergistic.
Joe Pantginis
analystUnderstood, understood.
Carl Spana
executiveUm—
Joe Pantginis
analystPigmentation?
Carl Spana
executiveThe skin darkening seen with the first generation of MC4R agonists — and there are actually several approved, bremelanotide being one of them — comes from activity at the melanocortin-1 receptor. And in the case of short-term use, it's not an issue, but when we move on to more chronic use in obese patients, it can be an issue for patients. They don't like the skin darkening. So to accomplish that, you need next-generation compounds that are really devoid of MC1R activity. And based on the extensive number of years I've been working in this field, we've been able to achieve that. Compounds that we are in final evaluation have substantial separation between the two receptors, and in fact, many of them are not active at MC1R, so we don't expect any skin darkening with those compounds. And then those are on the peptide front, and when we think about small molecules, that pharmacophore is much smaller, and it's really highly selective. MC4R doesn't have any MC1R activity at all.
Joe Pantginis
analystNo, that helps.
Carl Spana
executiveAppreciate it.
Joe Pantginis
analystOh, my apologies.
Carl Spana
executiveYes.
Joe Pantginis
analystRight. I only wanted to move over to the dry eye program, since I think it's terrific that you already enjoy such strong visibility and dialogue with the FDA, and, you know, I'm looking forward to these programs getting underway. So I suppose, you know, do you believe, or how far along are your business development discussions? But more on the logistical side, the FDA guidance—I just wanted to confirm, are these the same signs and symptoms as in MELODY-1? Or are they different? And you know, how would they appear to you when it comes to evaluating the primary endpoints in the end?
Carl Spana
executiveOkay, so let me sort of go in reverse order here. The symptom is precisely the same one that MELODY-1 used. The sign, though, is that we're switching from lissamine green to inferior corneal fluorescein staining, since every fluorescein stain hit significance at the 2-week time point in MELODY-1. Inferior corneal fluorescein staining is simply a superior sign compared with that — it's a broadly accepted sign employed in dry eye across these studies — so that's the one we're choosing, and once again, we have FDA agreement on using both of them in the study. As for being ready to launch, assuming the right financing and so forth, the protocols are assembled, the SAP is assembled, and the CROs have been hired and are done. So honestly, we're more or less set to move ahead the moment we lock in the appropriate funding. That ties into the first part of your question, which was: where do we stand on that? And I'd say we've seen quite strong interest on the corporate side. A lot of it was pending — many of those entities were in continuing talks, awaiting the results of the Type C meeting.
Carl Spana
executiveSo now that those are in hand, we've gone back to those entities, and we're currently in talks with them, working toward—hopefully working toward—what will be, you know, the close of a licensing deal or some kind of transaction. Beyond that, more recently we've seen some very encouraging uptake, with conversations involving larger funds that would also have interest in, you know, potentially providing funding for the phase III program and pushing it forward as well. So we're really coming at this from two directions. And obviously, I've stolen a bit of Steve's thunder, since Steve is actually the one leading those discussions. But I think we've been fairly pleased with how much progress we've been making.
Joe Pantginis
analystHearing about that optionality is great, and Carl, we appreciate the specifics.
Carl Spana
executiveAppreciate it, Joe.
Operator
operatorOur next question comes from John Newman at Canaccord Genuity. Go ahead and ask your question. Your line is open.
John Newman
analystGood morning, and thanks for taking the question. This one's for Carl. Carl, do you see potential to co-formulate some of your MC4R agonists with drugs such as tirzepatide? The reason I ask is that there's obviously been a revolution in weight loss treatment, which has been fantastic with the GLP-1s, but we do know that eventually at least some of those products will be selected for price reductions. One way to potentially address that, though, is combining the GLP-1s with novel molecules. So I'm just curious whether maybe over the long term — maybe not immediately, but longer term — that's a potential avenue for your compounds. Thanks.
Carl Spana
executiveSure. Yeah, so in that same vein, we haven’t actually undertaken any of that work yet. That said, I’d say it’s very doable. The formulations for these compounds — these are fairly soluble compounds, both the GLP-1s and the stuff we’re working with. So in that regard, it ought to be comparatively straightforward to develop formulations where the two are combined. Of course, I’m saying this without being the person who actually carries out the lab work, but from a theoretical perspective, I think it should be relatively easy to accomplish that — to bring the two together.
John Newman
analystAll right, that's excellent. Thanks very much.
Operator
operatorAt this point, we don't have any further questions waiting. I'd like to hand things back to Dr. Carl Spana so he can offer any closing remarks.
Carl Spana
executiveWell, Steve, myself, and everyone at Palatin would like to express our thanks to each of you for tuning in to the Palatin year-end fiscal 2024 call. I also want to thank the analysts for the thoughtful questions they raised. There's a great deal of excitement on our side. I mean, here we are — for a small company, we've got an enormous amount of opportunity in front of us, and we genuinely look forward to what we can deliver over the coming year, and to keeping all of you informed about our progress through, you know, press releases and quarterly calls and presentations at various scientific and investor meetings. With that said, we hope each of you has a great day, and we look forward to keeping you updated. Thank you.
Operator
operatorThanks to all of you. That brings today's conference call to an end. At this point you're welcome to hang up your phones, and I hope the rest of your day is great. We appreciate your joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.